530 related articles for article (PubMed ID: 18338422)
1. Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model.
Tuccinardi T; Schenone S; Bondavalli F; Brullo C; Bruno O; Mosti L; Zizzari AT; Tintori C; Manetti F; Ciampi O; Trincavelli ML; Martini C; Martinelli A; Botta M
ChemMedChem; 2008 Jun; 3(6):898-913. PubMed ID: 18338422
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and 3D QSAR of new pyrazolo[3,4-b]pyridines: potent and selective inhibitors of A1 adenosine receptors.
Manetti F; Schenone S; Bondavalli F; Brullo C; Bruno O; Ranise A; Mosti L; Menozzi G; Fossa P; Trincavelli ML; Martini C; Martinelli A; Tintori C; Botta M
J Med Chem; 2005 Nov; 48(23):7172-85. PubMed ID: 16279775
[TBL] [Abstract][Full Text] [Related]
3. Substituted pyrazolo[3,4-b]pyridines as human A1 adenosine antagonists: developments in understanding the receptor stereoselectivity.
Tuccinardi T; Zizzari AT; Brullo C; Daniele S; Musumeci F; Schenone S; Trincavelli ML; Martini C; Martinelli A; Giorgi G; Botta M
Org Biomol Chem; 2011 Jun; 9(12):4448-55. PubMed ID: 21390354
[TBL] [Abstract][Full Text] [Related]
4. New pyrazolo[3,4-b]pyridones as selective A(1) adenosine receptor antagonists: synthesis, biological evaluation and molecular modelling studies.
Fossa P; Pestarino M; Menozzi G; Mosti L; Schenone S; Ranise A; Bondavalli F; Trincavelli ML; Lucacchini A; Martini C
Org Biomol Chem; 2005 Jun; 3(12):2262-70. PubMed ID: 16010360
[TBL] [Abstract][Full Text] [Related]
5. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
6. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.
Cosimelli B; Greco G; Ehlardo M; Novellino E; Da Settimo F; Taliani S; La Motta C; Bellandi M; Tuccinardi T; Martinelli A; Ciampi O; Trincavelli ML; Martini C
J Med Chem; 2008 Mar; 51(6):1764-70. PubMed ID: 18269230
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.
Tafi A; Bernardini C; Botta M; Corelli F; Andreini M; Martinelli A; Ortore G; Baraldi PG; Fruttarolo F; Borea PA; Tuccinardi T
J Med Chem; 2006 Jul; 49(14):4085-97. PubMed ID: 16821770
[TBL] [Abstract][Full Text] [Related]
8. 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists.
Chang LC; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; Westerhout J; Spangenberg T; Brussee J; Ijzerman AP
J Med Chem; 2007 Feb; 50(4):828-34. PubMed ID: 17300165
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
[TBL] [Abstract][Full Text] [Related]
10. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
[TBL] [Abstract][Full Text] [Related]
11. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological assays and QSAR studies of N-(9-benzyl-2-phenyl-8-azapurin-6-yl)-amides as ligands for A1 adenosine receptors.
Giorgi I; Leonardi M; Pietra D; Biagi G; Borghini A; Massarelli I; Ciampi O; Bianucci AM
Bioorg Med Chem; 2009 Mar; 17(5):1817-30. PubMed ID: 19230680
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists.
Elsner J; Boeckler F; Heinemann FW; Hübner H; Gmeiner P
J Med Chem; 2005 Sep; 48(18):5771-9. PubMed ID: 16134944
[TBL] [Abstract][Full Text] [Related]
15. Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.
Taliani S; La Motta C; Mugnaini L; Simorini F; Salerno S; Marini AM; Da Settimo F; Cosconati S; Cosimelli B; Greco G; Limongelli V; Marinelli L; Novellino E; Ciampi O; Daniele S; Trincavelli ML; Martini C
J Med Chem; 2010 May; 53(10):3954-63. PubMed ID: 20408530
[TBL] [Abstract][Full Text] [Related]
16. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study.
Moro S; Braiuca P; Deflorian F; Ferrari C; Pastorin G; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2005 Jan; 48(1):152-62. PubMed ID: 15634009
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
18. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
Lenzi O; Colotta V; Catarzi D; Varano F; Poli D; Filacchioni G; Varani K; Vincenzi F; Borea PA; Paoletta S; Morizzo E; Moro S
J Med Chem; 2009 Dec; 52(23):7640-52. PubMed ID: 19743865
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies.
Yuzlenko O; Kieć-Kononowicz K
J Comput Chem; 2009 Jan; 30(1):14-32. PubMed ID: 18496794
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological activity and molecular modelling of new trisubstituted 8-azaadenines with high affinity for A1 adenosine receptors.
Giorgi I; Bianucci AM; Biagi G; Livi O; Scartoni V; Leonardi M; Pietra D; Coi A; Massarelli I; Nofal FA; Fiamingo FL; Anastasi P; Giannini G
Eur J Med Chem; 2007 Jan; 42(1):1-9. PubMed ID: 17028066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
